Imprese · 21/06/19991 min di lettura
SoloPak Laboratories, Inc.; Withdrawal of Approval of 1 New Drug Application and 38 Abbreviated New Drug Applications
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
The Food and Drug Administration (FDA) is withdrawing approval of 1 new drug application (NDA) and 38 abbreviated new drug applications (ANDA's). SoloPak Laboratories, Inc., notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.